openPR Logo
Press release

Oncology Biosimilars Market Prospects Outlook 2019-2027 and Top Key Players - Biocon, Celltrion , Dr. Reddy's Laboratories , Amgen , Intas Pharmaceuticals, Pfizer , Sandoz International GmbH (A Novartis Division)

05-07-2019 01:41 PM CET | Health & Medicine

Press release from: ReportsWeb

Oncology Biosimilars Market

Oncology Biosimilars Market

Biosimilars are the fastest-growing class of therapeutic products across the globe. Biosimilars are biologics that serves as interchangeable products offering additional treatment options to a branded drug counterpart, potentially reducing the cost of the prescribed biologics. The biosimilar therapies have been for chronic disease management and supportive care since a few years, however the use of these biosimilars are expected to be applied soon for treatment of various types of cancers referred to as oncology biosimilars.

The market for oncology biosimilars market is expected to witness growth due to extensive research undertaken by market players to bring biosimilars for cancer treatment in the market as well as rapid approval by regulatory authorities for commercialization of these products. However, high costs involved in the research and complexity involved in the formulation of these biologics are likely to hinder market growth.

The "Global Oncology Biosimilars Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a focus on the global market trend. The report aims to provide an overview of global oncology biosimilars market with detailed market segmentation by product, cancer type, and distribution channel. The global oncology biosimilars market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

Get Sample copy @ http://bit.ly/2DWa1ZT

Some of the key players influencing the market are:
Biocon, Celltrion , Dr. Reddy's Laboratories , Amgen , Intas Pharmaceuticals, Pfizer , Sandoz International GmbH (A Novartis Division), Teva Pharmaceutical Industries Ltd., Mylan N.V., and BIOCAD among others.

The global oncology biosimilars market is segmented on the basis of product, cancer type, and distribution channel. On the basis of product, the global oncology biosimilars market is segmented into monoclonal antibodies, Immunomodulators, and others. On the basis of cancer type, the global oncology biosimilars market is segmented in to lung cancer, colorectal cancer, cervical cancer, breast cancer, kidney cancer, stomach cancer, brain cancer, and others. On the basis of distribution channel, the oncology biosimilars market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

The oncology biosimilars market report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global oncology biosimilars market based product, cancer type, and distribution channel. It also provides market size and forecast till 2027 for overall oncology biosimilars market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.

Have any questions? Ask here @ http://bit.ly/2vJ54iM

North America dominated the oncology biosimilars market in 2017, owing to the rapid approval of biosimilars by US FDA. Moreover, various market players in the US and Canada have robust pipeline of biosimilars that are expected to be soon approved suggesting high growth rate of the region in the coming years. Asia Pacific on the other hand is expected witness the highest growth over the forecast period owing to the availability of immense opportunities in countries like India, China & Japan. Rising government initiatives for incorporating cost-efficient treatment options for various type of cancer in middle and low income economies of the region are expected to be the driving factors for Asian growth.

Table of Content:

1. Introduction
2. Key Takeaways
3. Oncology Biosimilars Market Landscape
4. Oncology Biosimilars Market - Key Industry Dynamics
5. Oncology Biosimilars Market - Global Analysis
6. Oncology Biosimilars Market Revenue and Forecasts to 2027 - By Product
7. Oncology Biosimilars Market Revenue and Forecasts to 2027 - By Cancer Type
8. Oncology Biosimilars Market Revenue and Forecasts to 2027 - By Distribution Channel
9. North America Oncology Biosimilars Market Revenue and Forecasts to 2027 - Country Analysis
10. Europe Oncology Biosimilars Market Revenue and Forecasts to 2027 - Country Analysis
11. Asia Pacific Oncology Biosimilars Market Revenue and Forecasts to 2027 - Country Analysis
12. Middle East and Africa (Mea) Oncology Biosimilars Market Revenue and Forecasts to 2027 - Country Analysis
13. South and Central America Oncology Biosimilars Market Revenue and Forecasts to 2027 - Country Analysis
14. Industry Landscape
15. Oncology Biosimilars Market, Key Company Profiles

Get Interesting Discount @ http://bit.ly/2JjQciE

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oncology Biosimilars Market Prospects Outlook 2019-2027 and Top Key Players - Biocon, Celltrion , Dr. Reddy's Laboratories , Amgen , Intas Pharmaceuticals, Pfizer , Sandoz International GmbH (A Novartis Division) here

News-ID: 1729907 • Views: 213

More Releases from ReportsWeb

Trending Report on Irrigation Automation Market by Growth, Demand & Opportunitie …
Global Irrigation Automation Market Analysis to 2030 is a specialized and in-depth study of the Irrigation Automation industry with a focus on the global market trend. The research report on Irrigation Automation Market provides comprehensive analysis on market status and development pattern, including types, applications, rising technology and region. Irrigation Automation Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a
Green Energy Market Will Raise Beyond Imagination over Period 2030
Green energy is energy that comes from natural sources such as wind, rain, sunlight, plants, geothermal and heat. These are renewable energy sources and the energy produced by them is called green energy which is free of all environmental hazards. Renewable energy technologies convert the energy from different natural sources such as sun, tides, wind and others, into its usable forms such as electricity. The renewable energy sector in India
Massive Growth of Hygienic Pressure Transmitters Market by 2027 Leading Players …
The optimum utilization of resources and high emphasis on industrial automation are some of the significant factors driving the growth of the hygienic pressure sensor market. Moreover, increasing development in industrial automation is anticipated to bring new opportunities for the hygienic pressure transmitter market. Leading Hygienic Pressure Transmitters Market Players: Dwyer Instruments, Inc., Emerson Electric Co., ESI Technology Ltd, Hitachi High-Tech Corporation., Honeywell International Inc, NAGANO KEIKI CO., LTD., OMEGA Engineering
Powered Smart Card Market Study Navigating the Future Growth Outlook KENPLAS Ind …
The rising demand for reliable and secure payment transactions, enhanced security for residential, offices, and commercial buildings is driving the growth of the powered smart card market. However, the high costs of migration to powered smart cards, misuse of stolen / lost contactless cards may restrain the growth of the powered smart card market. Furthermore, the growing convergence of powered smart cards as well as additional services offered by the

All 5 Releases


More Releases for Biosimilars

PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on